What if gene-edited pig-organ transplants fail with deadly rejection?
A xenotransplant hyperacute-rejection failure freezes a tiny pre-revenue sector (eGenesis, United Therapeutics) — micro-cap idiosyncratic risk with no macro footprint. Closest rhyme is the gene-therapy safety halts of 2021-22 (bluebird/Novartis Zolgensma deaths) that gutted the names but not the tape. The risk-off crypto cascade massively overstates transmission; effectively zero cross-asset impact.
how we built this number — every step
The class rate is measured from our dated, sourced event library (decade-normalized Poisson — the full table is public at base_rates.json). The variant’s share within its class is the analyst’s editorial call, published so you can audit it. A wider range means thinner precedent. Full recipe: methodology · scored at Reality Check.
The butterfly cascade
How this trigger trickles across markets, left → right — the root shock, its first‑order moves, then the ripple effects. Drag any node; tap a market for its real price history.
Resolution timeline — how this probability is moving
Our model's odds (gold) over time vs the crowd's (Polymarket, blue), from the past toward the 1–3 years horizon. Each dot is a real macro event that nudged the probability — green pushed it up, red pushed it down. Tap a dot for the source. The gold path is an illustrative reconstruction anchored to today's estimate — real dated events, not a live re-estimate history.
What it would mean
If this plays out, it is a mixed shock. Xenotransplant trial of gene-edited pig kidneys fails with hyperacute rejection deaths, freezing the xenotransplantation sector. The trigger decomposes into signed root‑shocks — Risk appetite ▼ — which propagate through our causal graph to the markets below.
If it happens — the markets it would move
Biggest moves first. Projected moves are cascade-model priors; hist A–B% = what comparable past events actually did (measured abnormal returns), and model prior · unmeasured marks markets with no analogue backing yet. Tap any market for its price history.
| Market | Class | Projected move |
|---|
Historical precedent — what analogous events actually did
Across 40 analogous events (overlap‑weighted), as abnormal returns — market beta stripped, so it's the event's own effect, not the market backdrop. Shown at 20 days (persistent) and 5 days (immediate); ↺ fades = the two horizons disagree. Confidence = consistency × sample × significance.
| Asset | History says | Abnormal (20d · 5d) | Hit | n | Confidence | vs cascade |
|---|---|---|---|---|---|---|
| Bitcoin BTC | SHORT | -4.5% · 5d -3.4% | 60% | 40 | 0.15 | · |
| Gold XAU | LONG | +0.2% · 5d -0.3% ↺ fades | 57% | 40 | 0.13 | · |
| High-yield credit HYG | SHORT | -0.0% · 5d +0.2% ↺ fades | 55% | 40 | 0.07 | · |
| US dollar DXY | SHORT | -0.0% · 5d -0.1% | 53% | 40 | 0.05 | · |
| Volatility VIX | SHORT | -0.8% · 5d +0.1% ↺ fades | 53% | 40 | 0.04 | · |
| 10y yield DGS10 | LONG | +2bp · 5d +1bp | 53% | 40 | 0.04 | · |
Why this probability
Pig-kidney xeno trial deaths possible but hyperacute-rejection-driven sector freeze is rare/structural. A base‑rate‑anchored prior, continuously scored against what actually happens — not a forecast.